| Kristopher K Mcjenkin, MD | |
|
105 Bass Plantation Dr, Apt 607, Macon, GA 31210-5735 | |
| (770) 355-2152 | |
| (770) 355-2152 |
| Full Name | Kristopher K Mcjenkin |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 12 Years |
| Location | 105 Bass Plantation Dr, Macon, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255779351 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 6086 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Medical Center, Navicent Health (the) | Macon, GA | Hospital |
| Memorial University Medical Center | Savannah, GA | Hospital |
| Houston Medical Center | Warner robins, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Houston Hospitalist Group Llc | 2769813906 | 40 |
| Cogent Healthcare Of Macon, Llc | 9234104019 | 52 |
News Archive
LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 19-23.
A group of researchers recently expanded upon the limited prior research examining the effects of soy and whey protein supplementation on testosterone, sex hormone binding globulin (SHBG), and cortisol responses to an acute bout of resistance exercise.
Sharks are, by tradition, the eternal threat facing divers. Yet, a diver is quite a lot more unlikely to meet such a creature under the water than, at some time or another, to come up against an even greater danger – hypothermia, or exposure.
Infinity Pharmaceuticals, Inc. today announced that Phase 1 data of its novel Hedgehog pathway inhibitor, IPI-926, will be presented during the 35th Congress of the European Society of Molecular Oncology (ESMO), in Milan, Italy.
A new study has found that the little-known member of the human herpesvirus family called HHV-6A infects the lining of the uterus in 43% of women with unexplained infertility but cannot be found in uterine lining of fertile women. The study was conducted by investigators at the University of Ferrara, Italy.
› Verified 5 days ago
| Entity Name | Cogent Healthcare Of Macon, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073564217 PECOS PAC ID: 9234104019 Enrollment ID: O20040826000927 |
News Archive
LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 19-23.
A group of researchers recently expanded upon the limited prior research examining the effects of soy and whey protein supplementation on testosterone, sex hormone binding globulin (SHBG), and cortisol responses to an acute bout of resistance exercise.
Sharks are, by tradition, the eternal threat facing divers. Yet, a diver is quite a lot more unlikely to meet such a creature under the water than, at some time or another, to come up against an even greater danger – hypothermia, or exposure.
Infinity Pharmaceuticals, Inc. today announced that Phase 1 data of its novel Hedgehog pathway inhibitor, IPI-926, will be presented during the 35th Congress of the European Society of Molecular Oncology (ESMO), in Milan, Italy.
A new study has found that the little-known member of the human herpesvirus family called HHV-6A infects the lining of the uterus in 43% of women with unexplained infertility but cannot be found in uterine lining of fertile women. The study was conducted by investigators at the University of Ferrara, Italy.
› Verified 5 days ago
| Entity Name | North Atlanta Professional Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316959869 PECOS PAC ID: 0840291944 Enrollment ID: O20070116000197 |
News Archive
LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 19-23.
A group of researchers recently expanded upon the limited prior research examining the effects of soy and whey protein supplementation on testosterone, sex hormone binding globulin (SHBG), and cortisol responses to an acute bout of resistance exercise.
Sharks are, by tradition, the eternal threat facing divers. Yet, a diver is quite a lot more unlikely to meet such a creature under the water than, at some time or another, to come up against an even greater danger – hypothermia, or exposure.
Infinity Pharmaceuticals, Inc. today announced that Phase 1 data of its novel Hedgehog pathway inhibitor, IPI-926, will be presented during the 35th Congress of the European Society of Molecular Oncology (ESMO), in Milan, Italy.
A new study has found that the little-known member of the human herpesvirus family called HHV-6A infects the lining of the uterus in 43% of women with unexplained infertility but cannot be found in uterine lining of fertile women. The study was conducted by investigators at the University of Ferrara, Italy.
› Verified 5 days ago
| Entity Name | Gwinnett Physician Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578574661 PECOS PAC ID: 9133211139 Enrollment ID: O20070822001035 |
News Archive
LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 19-23.
A group of researchers recently expanded upon the limited prior research examining the effects of soy and whey protein supplementation on testosterone, sex hormone binding globulin (SHBG), and cortisol responses to an acute bout of resistance exercise.
Sharks are, by tradition, the eternal threat facing divers. Yet, a diver is quite a lot more unlikely to meet such a creature under the water than, at some time or another, to come up against an even greater danger – hypothermia, or exposure.
Infinity Pharmaceuticals, Inc. today announced that Phase 1 data of its novel Hedgehog pathway inhibitor, IPI-926, will be presented during the 35th Congress of the European Society of Molecular Oncology (ESMO), in Milan, Italy.
A new study has found that the little-known member of the human herpesvirus family called HHV-6A infects the lining of the uterus in 43% of women with unexplained infertility but cannot be found in uterine lining of fertile women. The study was conducted by investigators at the University of Ferrara, Italy.
› Verified 5 days ago
| Entity Name | Marcy Inpatient Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396154159 PECOS PAC ID: 0244555613 Enrollment ID: O20150205000737 |
News Archive
LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 19-23.
A group of researchers recently expanded upon the limited prior research examining the effects of soy and whey protein supplementation on testosterone, sex hormone binding globulin (SHBG), and cortisol responses to an acute bout of resistance exercise.
Sharks are, by tradition, the eternal threat facing divers. Yet, a diver is quite a lot more unlikely to meet such a creature under the water than, at some time or another, to come up against an even greater danger – hypothermia, or exposure.
Infinity Pharmaceuticals, Inc. today announced that Phase 1 data of its novel Hedgehog pathway inhibitor, IPI-926, will be presented during the 35th Congress of the European Society of Molecular Oncology (ESMO), in Milan, Italy.
A new study has found that the little-known member of the human herpesvirus family called HHV-6A infects the lining of the uterus in 43% of women with unexplained infertility but cannot be found in uterine lining of fertile women. The study was conducted by investigators at the University of Ferrara, Italy.
› Verified 5 days ago
| Entity Name | Anemonefish Inpatient Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033514716 PECOS PAC ID: 7012236664 Enrollment ID: O20150501001344 |
News Archive
LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 19-23.
A group of researchers recently expanded upon the limited prior research examining the effects of soy and whey protein supplementation on testosterone, sex hormone binding globulin (SHBG), and cortisol responses to an acute bout of resistance exercise.
Sharks are, by tradition, the eternal threat facing divers. Yet, a diver is quite a lot more unlikely to meet such a creature under the water than, at some time or another, to come up against an even greater danger – hypothermia, or exposure.
Infinity Pharmaceuticals, Inc. today announced that Phase 1 data of its novel Hedgehog pathway inhibitor, IPI-926, will be presented during the 35th Congress of the European Society of Molecular Oncology (ESMO), in Milan, Italy.
A new study has found that the little-known member of the human herpesvirus family called HHV-6A infects the lining of the uterus in 43% of women with unexplained infertility but cannot be found in uterine lining of fertile women. The study was conducted by investigators at the University of Ferrara, Italy.
› Verified 5 days ago
| Entity Name | Houston Hospitalist Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962040147 PECOS PAC ID: 2769813906 Enrollment ID: O20200504000786 |
News Archive
LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 19-23.
A group of researchers recently expanded upon the limited prior research examining the effects of soy and whey protein supplementation on testosterone, sex hormone binding globulin (SHBG), and cortisol responses to an acute bout of resistance exercise.
Sharks are, by tradition, the eternal threat facing divers. Yet, a diver is quite a lot more unlikely to meet such a creature under the water than, at some time or another, to come up against an even greater danger – hypothermia, or exposure.
Infinity Pharmaceuticals, Inc. today announced that Phase 1 data of its novel Hedgehog pathway inhibitor, IPI-926, will be presented during the 35th Congress of the European Society of Molecular Oncology (ESMO), in Milan, Italy.
A new study has found that the little-known member of the human herpesvirus family called HHV-6A infects the lining of the uterus in 43% of women with unexplained infertility but cannot be found in uterine lining of fertile women. The study was conducted by investigators at the University of Ferrara, Italy.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kristopher K Mcjenkin, MD 535 Coliseum Dr Ste B, Macon, GA 31217-0106 Ph: () - | Kristopher K Mcjenkin, MD 105 Bass Plantation Dr, Apt 607, Macon, GA 31210-5735 Ph: (770) 355-2152 |
News Archive
LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 19-23.
A group of researchers recently expanded upon the limited prior research examining the effects of soy and whey protein supplementation on testosterone, sex hormone binding globulin (SHBG), and cortisol responses to an acute bout of resistance exercise.
Sharks are, by tradition, the eternal threat facing divers. Yet, a diver is quite a lot more unlikely to meet such a creature under the water than, at some time or another, to come up against an even greater danger – hypothermia, or exposure.
Infinity Pharmaceuticals, Inc. today announced that Phase 1 data of its novel Hedgehog pathway inhibitor, IPI-926, will be presented during the 35th Congress of the European Society of Molecular Oncology (ESMO), in Milan, Italy.
A new study has found that the little-known member of the human herpesvirus family called HHV-6A infects the lining of the uterus in 43% of women with unexplained infertility but cannot be found in uterine lining of fertile women. The study was conducted by investigators at the University of Ferrara, Italy.
› Verified 5 days ago
Dr. Shuichi Nakai, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3780 Eisenhower Pkwy, Macon, GA 31206 Phone: 478-633-5550 Fax: 478-633-7287 | |
Sam G Amporful, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 721 Riverside Drive Lane, Macon, GA 31201 Phone: 478-259-3439 Fax: 478-254-2733 | |
Mrs. Stephanie Faye Bennett, Family Medicine Medicare: Medicare Enrolled Practice Location: 101 Gateway Drive, Macon, GA 31210 Phone: 478-210-1670 | |
Dr. Robert C Jones, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3200 Riverside Dr Ste B300, Macon, GA 31210 Phone: 478-405-5252 Fax: 478-477-8411 | |
Alice Rose House, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1550 College St, Suite A, Macon, GA 31207 Phone: 478-301-4111 Fax: 478-301-5812 | |
Dione Duc, Family Medicine Medicare: Medicare Enrolled Practice Location: 777 Hemlock St # 104, Macon, GA 31201 Phone: 478-633-7550 Fax: 478-633-3235 | |
Collier Branan Gladin Jr., M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 140 N Crest Blvd, Macon, GA 31210 Phone: 478-757-8335 Fax: 478-757-8353 |